To assess the use of two-drug antiretroviral regimens (2DR) and virologic and immunologic outcomes compared to three-drug regimens (3DR) in the EuroSIDA cohort.
Multicentre, prospective cohort study.
Logistic regression was used to analyse the uptake and outcomes among HIV-positive individuals who started or switched to a 2DR compared to those on a 3DR. Virologic outcomes were assessed on-treatment as the proportion of individuals with controlled viral load (VL, <400 copies/mL), or with a composite modified FDA snapshot endpoint (mFDA), with mFDA success defined as controlled VL at 6- or 12-months for individuals with a known VL, no regimen changes, AIDS or death. Immunologic response was defined as a 100 cells/μL or a 25% increase in CD4 counts from baseline.
Between 1/7/2010-31/12/2016, 423 individuals started or switched to a 2DR (8 antiretroviral-naïve) and 4347 started a 3DR (566 naïve). Individuals on 2DR tended to have suppressed VL, higher CD4 cell counts and more comorbidities at baseline compared to those on 3DR. There were no differences in the proportions of individuals who obtained on-treatment or mFDA success, and no significant differences in the adjusted odds ratios for mFDA success or immunologic responses between the 2DR and 3DR groups at 6- or 12-months.
In routine clinical practice, 2DR were largely used for virologically suppressed individuals with higher cumulative exposure to ARVs and comorbidities. Virologic and immunologic outcomes were similar among those on 2DR or 3DR, although confounding by indication cannot be fully excluded due to the observational nature of the study.
aCHIP, University of Copenhagen, Denmark
bUniversity College London, UK
cInstitute of Tropical Medicine, Antwerp, Belgium
dDepartment of Infectious Diseases, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
eRoyal Sussex County Hospital, Brighton, UK
fHvidovre Hospital, University of Copenhagen, Denmark
gGomel State Medical University, Belarus
hHospital Ramon y Cajal, Madrid, Spain
iSzpital Specjalistyczny, Chorzów Poland
jUniversity Hospital of Infectious Diseases, Zagreb, Croatia
kVilnius University, Faculty of Medicine, Vilnius University Hospital Santaros Klinikos
lNovgorod Centre for AIDS Prevention and Control, Russia
mKaplan Medical Center, Rehovot, Israel
nHospital JM Ramos Mejia, Buenos Aires, Argentina
oSapienza University of Rome, Italy
pMedizinische Hochschule Hannover, Germany
qCentre Hospitalier de Luxembourg
rViiV Healthcare, RTP, North Carolina, USA.
Correspondence to Bastian Neesgaard, MD, CHIP, Department of Infectious Diseases, Section 2100, Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark. Tel: +45 35 45 57 70; fax: +45 35 45 57 58; e-mail: Bastian.email@example.com
Received 15 March, 2019
Revised 9 June, 2019
Accepted 16 June, 2019
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).